Arca
Skip to content
Tools
Tools

SEMA4D: Semaphorin-4D

Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on SEMA4D, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 30

      Phase 21

      • Pepinemab

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        PepinemabPhase 2VaccinexAntibodyInhibitorSemaphorin-4D inhibitor3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
        Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaPepinemabPhase 1 / Phase 2Active, not recruitingVaccinex Inc.Nov 1, 2021
        VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaPepinemabPhase 1Active, not recruitingEmory UniversityDec 7, 2018
        VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerPepinemabPhase 1Active, not recruitingEmory UniversityOct 1, 2018

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Skin aging0.44
        • Intelligence0.28
        • Placental abruption0.19
        • Otosclerosis0.15
        • Neoplasm0.13
        • Head and neck squamous cell carcinoma0.10

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630887, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q92854, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.